Evaluation of tacrolimus (Prograf) intraportal infusion during the implantation and the protective effect on ischemia reperfusion injury in orthotopic liver transplant recipients single center study.

Trial Profile

Evaluation of tacrolimus (Prograf) intraportal infusion during the implantation and the protective effect on ischemia reperfusion injury in orthotopic liver transplant recipients single center study.

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2015

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Liver transplant rejection; Reperfusion injury
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Dec 2010 Last checked against ClinicalTrials.gov record.
    • 07 Dec 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top